April 9, 2011 -- ChinaBio® published its review of last year’s activity in China life science – “China Life Science 2010: A Great Leap Forward” – showing new records in every important metric; China NT Pharma will price a $275 million IPO in Hong Kong on April 13; China Medical System Holdings paid almost $200 million to acquire Tianjin Precede Medical Trade Development; Ascletis, a US-China biopharma startup, announced a huge $100 million Series A funding round conducted among angel investors; in an exclusive ChinaBio® interview, Ascletis’ CEO, Jinxi Wu, said the company has grants to extend the $100 million; Jilin Aodong Medicine made a $2 million investment into San Diego’s Vital Therapies and may add $25 million more; Keck Graduate Institute of Applied Life Sciences and ChinaBio® will offer summer internships in China; and Pfizer will co-promote a hypertension drug from Daiichi Sankyo Pharma in China. More details…..
Stock Symbols: (HK: 01011) (HK: 867) (SHE: 000623) (NYSE: PFE) (TSE: 4568)
